NCT02966106

Brief Summary

rTMS has appeared a potential new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the brain through a time varying magnetic field. ). Research on rTMS reports of minimal side effects of the method . The majority of clinically controlled studies have used high frequency stimulation of the left frontal cortex . Fewer studies have used right prefrontal, which has less side effects, such as local discomfort and a lower risk of releasing epileptic seizures, than high frequency stimulation .Both stimulus models has been shown to have statistically significant antidepressant effect and recent research clearly indicates that low frequency rTMS of the right prefrontal cortex i associated with an antidepressant effect at the same level as the high frequency model. Therefore the investigators want to examine the antidepressant effect of a specific rTMS low frequency model in a clinical setting using a placebo controlled, randomized double blind design.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2016

Shorter than P25 for not_applicable depression

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 15, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 17, 2016

Completed
14 days until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

November 29, 2017

Status Verified

November 1, 2016

Enrollment Period

6 months

First QC Date

November 15, 2016

Last Update Submit

November 28, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • remission

    the number of patients obtaining a Hamilton-17 item total score of \< 8

    8 weeks

Secondary Outcomes (2)

  • Response

    8 weeks

  • Cognitive function

    8 weeks

Study Arms (2)

Right prefrontal low frequency rTMS.

ACTIVE COMPARATOR

Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval

Device: Right prefrontal low frequency rTMS

Sham-rTMS

PLACEBO COMPARATOR

Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval

Other: Sham-rTMS

Interventions

A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval

Right prefrontal low frequency rTMS.

Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval

Sham-rTMS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Out-patients referred to Aarhus University Hospital, Risskov
  • Moderate-severe uni- and bipolar depression according to ICD-10
  • Age 18-80 years

You may not qualify if:

  • Organic brain disease.
  • Epileptic seizure \< 2 years
  • Patients with implanted metal parts in the brain or chest
  • Patients with pacemaker
  • Medical diseases with cerebral impact
  • Serious suicidal danger

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Poul Erik Buchholtz, MD

    Aarhus University Hospital, Risskov

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2016

First Posted

November 17, 2016

Study Start

December 1, 2016

Primary Completion

June 1, 2017

Study Completion

December 1, 2017

Last Updated

November 29, 2017

Record last verified: 2016-11

Data Sharing

IPD Sharing
Will not share